According to a study, a novel risk prediction score outperforms present guidelines for the prognosis of VTE (venous thromboembolism) in MM (multiple myeloma). Kristen M. Sanfilippo—from VA St. Louis Health Care System—along with colleagues sought to advance and authenticate a risk prediction score for VTE in MM and review the performance of the existing IMWG (International Myeloma Working Group)/NCCN (National Comprehensive Cancer Network) rules. A risk score was developed by using data of 4,446 patients at the VACCR (Veterans Administration Central Cancer Registry) with newly identified MM starting chemotherapy. This score was authenticated amongst 4,256 patients from the SEER (Surveillance, Epidemiology, End Results) database. The study was published in the American Journal of Hematology.
The investigators merged independent predictors of VTE to form the IMPEDE VTE score (counting body mass index, immunomodulatory agent, erythropoietin stimulating agent, Asian ethnicity/race, dexamethasone/doxorubicin, tunneled line/central venous catheter, VTE history, and existing thromboprophylaxis). The derivation group had satisfactory intolerance for the score (C-statistic was 0.66). As the score surged, the peril for VTE surged considerably. The IMPEDE VTE had a C-statistic of 0.64 in the external validation group. The researchers stated, “This data indicates that the IMPEDE VTE score can replace the peril stratification in the existing guidelines for the diagnosis of patients having MM at high risk of VTE.”
On a related note, recently, researchers identified health conditions that can be possibly misdiagnosed. Estimates show that over 100,000 Americans die or are eternally disabled every year owing to medical diagnoses that primarily miss conditions or delayed or are wrong. A research team reported it has recognized three main disease categories—such as infections, vascular events, and cancers—that sum up for almost three-fourths of all severe harms from diagnostic errors. The research was published in the journal Diagnosis.